Rationale for neoadjuvant immunotherapy in head and neck squamous cell carcinoma

Keyphrases

• Head-and-neck Cancer 100%
• Head-and-neck Squamous Cell Carcinoma (HNSCC) 100%
• Neoadjuvant Immunotherapy 100%
• Metastatic Spread 50%
• Potential Gains 50%
• Trial Results 50%
• Distant Metastasis 50%
• Adjuvant Therapy 50%
• Tumor Response 50%
• Definitive Treatment 50%
• Systemic Therapy 50%
• Immune Checkpoint Inhibitors 50%
• Neoadjuvant 50%
• Clinical Benefit 50%
• Immune Therapy 50%
• Resectable Disease 50%
• Tumor Downstaging 50%
• Recurrent Metastatic 50%
• Early Introduction 50%
• Extent of Surgery 50%
• Neoadjuvant Strategies 50%

Medicine and Dentistry

• Immunotherapy 100%
• Head and Neck Squamous Cell Carcinoma 100%
• Neoplasm 66%
• Head and Neck Cancer 66%
• Biological Marker 33%
• Systemic Therapy 33%
• Immune Checkpoint Inhibitor 33%
• Adjuvant Therapy 33%
• Immunity 33%
• Diseases 33%

Pharmacology, Toxicology and Pharmaceutical Science

• Immunotherapy 100%
• Head and Neck Squamous Cell Carcinoma 100%
• Neoplasm 66%
• Head and Neck Cancer 66%
• Biological Marker 33%
• Immune Checkpoint Inhibitor 33%
• Diseases 33%